Learn More About the Contents of the Medical Report
- Treatment recommendations based on somatic variants. More…
- Tumor to Normal Tissue Comparison. More…
- Determination of tumor mutational burden (TMB) und microsatellite instability (MSI). More…
- Illustration of tumor-relevant signaling pathways. More…
- Analysis of single nucleotide variants (SNVs), insertions and deletions (INDELs), translocations, and copy number variants (CNVs). More…
- Liquid Biopsy. More…
- Frequently Asked Questions. More…
About Tumor Development
Guidance on potentially effective drugs
Tumor to Normal Tissue Comparison
The Only Accurate Way to Determine Somatic Variants
The Basis for Therapeutic Decisions on Immunotherapies with Checkpoint Inhibitors
For a Detailed Understanding of Altered Signaling
Determination of Deletions/Amplifications for Highest Therapeutic Yield
Access to Tumor Tissue by Blood Analysis
Liquid biopsy is a method to access tumor DNA when surgery is not possible. Another important aspect is that a tissue sample only shows a part of a tumor disease. It is a single snapshot of a tumor over time and space and usually does not consider the tumor overall heterogeneity.
Liquid biopsy has the potential to provide a more complete genetic signature of the patient’s entire tumor burden. This is because tumor material, such as cell- free tumor DNA (ctDNA), is released from all parts of a tumor and all tumor sites in the body into the circulation.
Currently, the best approach for liquid biopsies implements is using ctDNA from blood samples.
Note: cfDNA referrs to the sum of all cell-free DNA, regardless if derived from normal tissue or tumor tissue. ctDNA referrs to DNA derived from tumor tissue only.
However, it should be noted that ctDNA cannot be distinguished from cell-free DNA derived from normal cells. Therefore, the tumor content in the sample can only be determined after sequencing. Samples with a low fraction of ctDNA to cfDNA (<20%) cannot be used for analysis, We at CeGaT have established and validated liquid biopsy analysis of cell-free DNA as a regular product. We offer our full somatic tumor panel using ctDNA from blood samples.
Following the literature (Corcoran and Chabner 2018) and considering the limitations of the liquid biopsy approach, we recommend in the first place using a standard tumor tissue sample and performing analysis by liquid biopsy when no tumor tissue is available. The most thorough analysis of course is to analyze both – a standard tissue biopsy and a liquid biopsy sample concurrently. This approach would combine the robust detection of genetic alterations in tissue samples with the possibility to asses a more comprehensive genetic profiling of the entire tumor disease.